相关实验视频
Updated: Jul 6, 2025

08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.0K
患有固体恶性瘤的患者的COVID-19疫苗接种结果:从广泛的现实数据和倾向得分匹配分析中获得的见解
George Dimitrov1, Krasimir Kalinov2, Trifon Valkov3
1Department of Medical Oncology, Medical University of Sofia, University Hospital "Tsaritsa Yoanna", Sofia, Bulgaria.
American journal of infection control
|December 29, 2023
概括
接种COVID-19疫苗显著降低了固体瘤患者的死亡率,特别是老年人和胸内恶性瘤患者. 然而,没有观察到对Delta或Omicron变种的好处.
科学领域:
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 患有固体恶性瘤的患者面临严重COVID-19结局的风险增加.
- 了解COVID-19疫苗接种对这一弱势群体的影响对于公共卫生战略至关重要.
研究的目的:
- 为了评估COVID-19疫苗接种对单独固体恶性瘤患者死亡率的影响.
- 为了确定从疫苗接种中获益最多的癌症患者的子组.
主要方法:
- 从2020年3月至2022年6月期间,对1,126,946例COVID-19病例进行了回顾性分析.
- 完全接种疫苗和未接种疫苗的队列之间的死亡率的比较,使用后勤回归和倾向得分匹配.
- 分析考虑了年龄,性别,癌症类型,疫苗类型和病毒变异.
主要成果:
- 接种疫苗的患有固体恶性瘤的患者死亡率降低 (OR 0.169>63年).
- 在非ICU和ICU环境中,以及胸内恶性瘤和息治疗中观察到好处.
- 没有发现对Delta和Omicron变种有显著的益处;在未接种疫苗的男性中发现更高的致命风险>63.
结论:
- 接种COVID-19疫苗对患有单独固体恶性瘤的患者,特别是老年人和患有特定癌症类型的患者提供了生存益处.
- 接种疫苗对较新的变种 (三角形,奥米克朗) 的有效性较低.
- 患有晚期疾病,接受息治疗或胸内恶性瘤的患者显示疫苗接种有好处.
相关概念视频
Cancer Vaccines
370
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
370
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Cancer Survival Analysis
355
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
355
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K

